Brief: Mabion Signs Deal With Oddifact Sas On Preparing Mabioncd20 For FDA Consultation
16/06/2026 10:09
BRIEF-Mabion Signs Deal With Oddifact Sas On Preparing Mabioncd20 For FDA Consultation June 16 (Reuters) - Mabion SA MABP.WA:
SIGNS AGREEMENT WITH ODDIFACT SAS FOR FIRST STAGE OF COOPERATION ON PREPARING MABIONCD20 FOR FDA CONSULTATION
POTENTIAL ANNUAL MARKET VALUE OF CD20 TREATMENT IN U.S. ESTIMATED AT $100 MILLION
FOLLOWING DEAL COMPANY REVERSES 4.8 MILLION ZLOTY INVENTORY WRITE-DOWN
Source text: ID:nEM5yMqbMa
Further company coverage: MABP.WA
(Reporting by Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Mabion SA
See all newsBrief: Mabion Signs Annex To Extend Production Agreement With Novavax To End of 2029
Brief: Mabion Signs Deal With Oddifact Sas On Preparing Mabioncd20 For FDA Consultation
Brief: Mabion Q1 Net Loss 9.7 Million Zlotys
Brief: Mabion Signs LoI With Oddifact On Use Of MabionCD20 Drug For Orphan Diseases
Brief: Mabion FY Net Loss 62.6 Million Zlotys